within Pharmacolibrary.Drugs.ATC.A;

model A03FA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.3383333333333333,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.0060999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009233333333333335,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Itopride is a prokinetic agent, acting as a dopamine D2 receptor antagonist and acetylcholinesterase inhibitor, primarily used for the treatment of gastrointestinal motility disorders such as functional dyspepsia. It is currently approved and used in several countries, particularly in Asia, but not in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic profile in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li>Bijay Kumar Sahoo, Ayan Das, Sangita Agarwal, Uttam Bhaumik, Anirbandeep Bose, Debotri Ghosh, Bikash Roy, Tapan Kumar Pal,Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.,Arzneimittel-Forschung,2009<a href='https://pubmed.ncbi.nlm.nih.gov/19856792/'>https://pubmed.ncbi.nlm.nih.gov/19856792/</a></li><li>Makiko Shimizu, Shotaro Uehara, Hiroshi Suemizu, Hiroshi Yamazaki,InÂ vivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice.,Drug metabolism and pharmacokinetics,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33513464/'>https://pubmed.ncbi.nlm.nih.gov/33513464/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03FA07;
